Inhalation Drug Delivery News

  1. BiondVax Signs Definitive Collaboration Agreement For The Development Of A Pipeline Of Innovative Nanosized Antibody (NanoAb) Therapies 3/25/2022

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced the signing of definitive agreements with the Max Planck Society, the parent organization of the Max Planck Institute for Multidisciplinary Sciences (MPI), and the University Medical Center Göttingen (UMG), both in Germany, to enter into a strategic collaboration for the development of innovative nanosized antibodies (NanoAbs)

  2. HCmed, Formosa Laboratories, And Formosa Pharmaceuticals Signed MoU To Form A Global CDMO For Inhalation Treatment Drugs 3/6/2022

    HCmed Innovations, Co., Ltd. (HCmed) announced that it has formed a strategic alliance with Formosa Laboratories, Inc. (TPEx: 4746) and Formosa Pharmaceuticals, Inc. (TPEx: 6838) to expand its business in the inhalation treatment field, providing contract development and manufacturing services